middle.news
Biotron Advances SedRx with EMA Regulatory Feedback
11:24am on Monday 13th of July, 2026 AEST
•
Healthcare
Read Story
Biotron Advances SedRx with EMA Regulatory Feedback
11:24am on Monday 13th of July, 2026 AEST
Key Points
EMA feedback clarifies SedRx regulatory pathway
Hybrid Marketing Authorisation Application ruled out
Biotron to plan pivotal clinical trials aligned with EMA
Shares issued to Sedarex vendors upon milestone achievement
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Biotron (ASX:BIT)
OPEN ARTICLE